Iron Carbohydrate complexes: Characteristics and regulatory challenges

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 20, Issue , 2015, Pages 149-170

  Mühlebach, Stefan ^a,b   Flühmann, Beat ^a  

^a Vifor (International) Inc   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Biodisposition and in vivo performance; Innate immune system; IV iron carbohydrates; Nanocolloidals; NBCDs; Polydispersity; Stepwise similarity approach (for follow on versions)

Indexed keywords

CARBOHYDRATE; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON NANOPARTICLE; IRON SACCHARATE; TRANSFERRIN;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPLEX FORMATION; DRUG APPROVAL; DRUG DISPOSITION; GEL PERMEATION CHROMATOGRAPHY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; IRON CARBOHYDRATE COMPLEX; IRON DEFICIENCY ANEMIA; KUPFFER CELL; NANOMEDICINE; OXIDATIVE STRESS; POLAROGRAPHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; THERAPEUTIC EQUIVALENCE; TRANSMISSION ELECTRON MICROSCOPY;

EID: 85057194881     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-3-319-16241-6_5     Document Type: Article

References (67)

1. Aguera ML, Martin-Malo A, Álvares de Lara MA et al (2014) The treatment with generic iv iron needs a higher dose of iron and ESA to keep hemoglobin stable. Nefrologia 34(S1):abstr 319
2. Andrews NC (2008) Forging a field: the golden age of iron biology. Blood 112:219-230
3. Auerbach M, Ballard H (2010) Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010:338-347
4. Bailie GR (2012) Comparison of rates of reported adverse events associated with IV iron products in the United States. Am J Health Syst Pharm 69(4):310-320
5. Bailie GR, Schuler C, Leggett RE, Levin R (2013a) Oxidative effect ferumoxytol and iron dextran on urinary bladder contraction and impact of antioxidants. Free Radic Antioxid 3(1):7-10
6. Bailie GR, Schuler C, Leggett RE, Li H, Li HD, Patadia H, Levin R (2013b) Oxidative effect of several intravenous iron complexes in the rat. Biometals 26(3):473-478
7. Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJ, Frigo TB, Lewis JM (2009) Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 39(6):489-496
8. Baker RD, Greer FR (2010) Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics 126(5):1040-1050
9. Beguin Y, Jaspers A (2014) Iron sucrose-characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency anemia in a broad range of therapeutic areas. Expert Opin Pharmacother 15(14):2087-2103
10. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, Antoni G, Langström B, Danilson BG (1999) Pharmacokinetics and red cell utilization of iron(III)-hydroxide-sucrose complex in anaemic patients-a study using positron emission tomography. Br J Haematol 104:296-302
11. Beshara S, Sorensen J, Lubberink M et al (2003) Pharmakokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anemic patients using positron emission tomography. Br J Haematol 120:853-859
12. Borchard G, Flühmann B, Mühlebach S (2012) Nanoparticle iron medicinal products-requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul Toxicol Pharmacol 64:324-328
13. Brissot P, Roperta M, Le Lana C, Loréala O (2012) Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta (BBA)-Gen Subj 1820(3):403-410
14. British Pharmacopoeia (2015) Monograph Iron Sucrose Injection. http://www.pharmacopoeia. co.uk/2015/access.htm Accessed Nov 2014
15. Chao Y, Karmali P, Simberg D (2012) Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles. Adv Exp Med Biol 733:115-123
16. Crichton RR, Danieslon BG, Geisser P (2008) Iron therapy with special emphasis on intravenous administration, 4th edn. Uni-Med, International Medical Publishers, London
17. Danielson B (2004) Structure, chemistry, and pharmacokinetics of intravenous iron agents. Am J Soc Nephrol 15:S93-S98
18. Danielson BG, Salmonson T, Derendorf H, Geisser P (1996) Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46(6):615-621
19. Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14(2):282-295
20. Ehmann F, Sakai-Kato K, Duncan R et al (2013) Next generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine 8(5):849-856
21. EMA (2011) Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. http://www.ema.europa.eu/ema/pages/includes/document/open_document.js p?webContentId=WC500105048. Accessed July 2014
22. EMA CHMP/SWP (2013) Draft reflection paper on the data requirements for intravenous ironbased nano-colloidal products developed with reference to an innovator medicinal product. EMA/CHMP/SWP/620008/2012, July 25, 2013. London, UK, European Medicines Agency. http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail. jsp?webContentId=WC500149496&murl=menus/document_library/document_library. jsp&mid=0b01ac058009a3dc. Accessed July 2014
23. Erni I, Oswald N, Rich HW, Schneider W (1984) Chemical characterization of iron (III)-hydroxide- dextrin complexes. A comparative study of commercial preparations with alleged reproductions used in the examination of bioavailability. Arzneimittelforschung 34(11):1555-1559
24. European Directorate for the Quality of Medicines & HealthCare. The European Pharmacopoeia in brief. EDQM brochure (2013) p 10. http://www.edqm.eu/en/Search-EDQM-website-519.html ?bStat=1&sChaineRecherchee=non-biological+complexes. Accessed Nov 2014
25. FDA (2012) Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm397017.pdf. Accessed Sept 2014
26. FDA (2013a) Draft guidance on iron sucrose. http://www.fda.gov/downloads/Drugs/Guidance- ComplianceRegulatoryInformation/Guidances/UCM297630.pdf. Accessed May 2014
27. FDA (2013b) Solicitation on the therapeutic equivalence of generic iron complex product. https:// www.fbo.gov/index?s=opportunity&mode=form&id=592788989854da145c8e7b6d103c898d &tab=core&tabmode=list&. Accessed July 2014
28. FDA (2014) Guidance for Industry. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product
29. Funk F, Long GJ, Hautot D, Büchi R, Christl I, Weidler PG (2001) Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the β-FeOOH or ferrihydrite structure. Hyperfine Interact 136(1-2):73-95
30. Fütterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P (2013) Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal 86:151-160
31. Geisser P, Burckhardt S (2011) The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3(1):12-33
32. Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117(3):285-297
33. Huch R, Schäfer R (2006) Iron deficiency and iron deficiency anemia. Georg Thieme Medical, Stuttgart
34. Jahn MR, Mrestani Y, Langguth P, Neubert RH (2007) CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA. Electrophoresis 28(14):2424-2429
35. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, Langguth P (2011) A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 78(3):480-491
36. KDIGO (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Chapter 2: Use of iron to treat anemia in CKD. Kidney Int Suppl 2(4):292-298
37. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S (2013) The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med 65:1174-1194
38. Krikorian S, Shafai G, Shamim K (2013) Managing iron deficiency anemia of CKD with IV iron. http://www.uspharmacist.com/content/d/featured%20articles/c/42386/. Accessed July 2014
39. Kudasheva DS, Lai J, Ulman A, Cowman MK (2004) Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem. 98(11):1757- 1769
40. Lee ES, Park BR, Kim JS, Choi GY, Lee JJ, Lee IS (2013) Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin 29(2):141-147
41. Martin-Malo A, Merino A, Carracedo J et al (2012) Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 27(6):2465-2471
42. Meier T, Schropp P, Pater C, Leoni AL, Khov-Tran VV, Elford P (2011) Physicochemical and toxicological characterization of a new generic iron sucrose preparation Arzneimittelforschung 61(2):112-119
43. Mircescu G, Critchon RR, Geisser P (2013) Iron therapy in renal anaemia, 1st edn. Uni-Med, International Medical Publishers, London
44. Mühlebach S, Vulto A, de Vlieger JSB, Weinstein V, Flühmann B, Shah VP (2013) The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead? Generics Biosimilars Initiat (GaBi) J 2(4):204-207
45. Muñoz M, Martin-Montanez E (2012) Ferric carboxymaltose for the treatment of iron-deficiency anemia. Expert Opin Pharmacother 13:907-921
46. Muñoz M, Gomez-Ramirez S, Liumbruno GM, Grazzini G (2014) Intravenous iron and safety: is the end of the debate on the horizon? Blood Transfus 12:287-289
47. Nicholas M (2014) Clinical development, immunogenicity, and interchangeability of follow-on complex drugs. Generics Biosimilars Initiat (GaBi) J 3(2):71-78
48. Nyström AM, Fadeel B (2012) Safety assessment of nanomaterials: implications for nanomedicine. J Controll Release 161:403-408
49. Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A (2011) Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 26(10):3262-3267
50. Schellekens H, Klinger E, Mühlebach S, Brin J, Storm G, Crommelin DJ (2011) The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 59(1):176-183
51. Schellekens H, Stegemann S, Weinstein V et al (2014) How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J 16(1):15-21
52. Schneider W (1988) Iron hydrolysis and the biochemistry of Iron-the interplay of hydoxide and biogenic ligands. Chimia 42:9-20
53. Schrier SL, Auerbach M, Mentzer WC, Landaw SA (2013) Treatment of anemia due to iron deficiency. http://www.uptodate.com/contents/treatment-of-the-adult-with-iron-deficiencyanemia# top. Accessed July 2014
54. Shah VP, Mühlebach S, Vulto A (2013) Workshop on the challenges in substitution of nonbiological complex drugs. Am J Health-Syst Pharm 70:1879-1880
55. Stefansson BV, Haraldsson B, Nilsson U (2011) Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 118(3):c249-256
56. Stein J, Dignass A, Chow KU (2012) Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 28(2):241-243
57. Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz YC et al (2014) Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci 1313(1):35-56
58. Toblli JE, Cao G, Oliveri L, Angerosa M (2009) Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 59(4):176-190
59. Toblli JE,Cao G, Oliveri L, Angerosa M (2011) Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Arzneimittelforschung 61(7):399-410
60. Toblli JE, Cao G, Oliveri L, Angerosa M (2012) Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 11(1):66-78
61. U.S. Pharmacopoeial Convention. Monographs in need of modernizaition, Iron sucrose injection (no. 207). Update Sept. 2014. http://www.usp.org/sites/default/files/usp_pdf/EN/ USPNF/2014-09-25_monographs_needing_modernization.xlsx. Accessed Nov 2014
62. Van Wyck D, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19(3):561-565
63. Vifor Pharma Ltd. Comment (2014) to the FDA 2013 guidance from Vifor Pharma Ltd, Sidley Austin LLP. http://www.regulations.gov/#!documentDetail;D=FDA-2007-D-0369-0289. Accessed July 2014
64. Walson P, Mühlebach S, Flühmann B (2014) First Asia-Pacific educational workshop on nonbiological complex drugs (NBCDs), Kuala Lumpur, Malaysia, 8 October 2013. Generics Biosimilars Initiat J 3(1):30-33
65. WHO (2008) Worldwide prevalence of anaemia 1993-2005. http://www.who.int/vmnis/publications/ anaemia_prevalence/en/. Accessed July 2014
66. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol Suppl 1:S4-8
67. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C (2010) Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 85(9):650-654